+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
N-Acetylglutamate Synthetase Deficiency Market - Global Forecast 2026-2032- Product Image
N-Acetylglutamate Synthetase Deficiency Market - Global Forecast 2026-2032- Product Image
Sale

N-Acetylglutamate Synthetase Deficiency Market - Global Forecast 2026-2032

  • Report

  • 180 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6126697
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The N-Acetylglutamate Synthetase Deficiency Market is projected to reach USD 219.79 Million in 2026. It is expected to continue growing at a CAGR of 11.31%, reaching USD 425.21 Million by 2032.

N-Acetylglutamate Synthetase Deficiency: Executive Summary

N-acetylglutamate synthetase deficiency (NAGS deficiency) is a rare inherited urea-cycle disorder in which impaired N-acetylglutamate production disrupts ammonia detoxification. The condition can present with neonatal hyperammonemia, recurrent metabolic crises, or later-onset neurological symptoms. Clinical outcomes depend heavily on rapid recognition, biochemical confirmation, dietary and medical management, and prevention of avoidable decompensation. This summary reviews diagnostic, therapeutic, healthcare-system, and policy considerations across major regions, country groups, and selected countries without presenting market estimates or forecasts.

Earlier Diagnosis and Integrated Care Are Reshaping NAGS Deficiency Management

Care is shifting from crisis-only treatment toward earlier identification, confirmatory genetic testing, structured emergency plans, and longitudinal metabolic follow-up. Expanded newborn-screening discussions, improved awareness of hyperammonemia, and access to specialist laboratories can shorten diagnostic delays, although screening practices remain uneven. Management increasingly combines ammonia-lowering interventions, individualized protein and energy plans, treatment of precipitating illness, genetic counseling, and coordination among metabolic physicians, intensivists, dietitians, neurologists, and pharmacists. Patient registries and standardized clinical pathways are also supporting more consistent documentation of symptoms, treatment response, and long-term outcomes.

Artificial Intelligence Can Support Recognition, Coordination, and Evidence Generation

Artificial intelligence may assist NAGS deficiency care by flagging hyperammonemia patterns in electronic records, identifying patients with unexplained encephalopathy, and supporting interpretation of longitudinal laboratory and clinical data. Natural-language tools can help organize emergency histories, medication records, and dietary information, while machine-learning methods may aid variant prioritization and registry quality control. These applications require specialist validation because NAGS deficiency is rare, datasets may be small or biased, and false alerts could delay urgent treatment or create inappropriate reassurance. Human oversight, privacy safeguards, transparent validation, and equitable access should remain central to deployment.

Regional Priorities Span Diagnostic Access, Specialist Capacity, and Continuity of Care

North America generally benefits from established metabolic centers, advanced biochemical testing, and multidisciplinary expertise, but geographic access and insurance-related barriers can still affect continuity. Europe has strong rare-disease networks and cross-border expertise, while differences in national screening, reimbursement, and referral pathways remain important. Asia-Pacific combines sophisticated specialist services in some settings with substantial diagnostic and laboratory gaps elsewhere. Latin America faces uneven access to confirmatory testing, emergency metabolic care, and specialized nutrition support. The Middle East is developing rare-disease infrastructure, with referral concentration and genetic-counseling capacity varying by country. Africa commonly confronts limited specialist coverage, laboratory constraints, and delayed recognition, making clinician education, referral networks, and practical emergency protocols particularly important.

International Groups Highlight Shared Needs but Uneven Health-System Readiness

ASEAN countries share priorities around clinician training, newborn and metabolic screening capacity, cross-border referral, and affordability of specialized care, although health-system resources differ substantially. BRICS members have significant clinical and research capabilities but require stronger coordination between urban specialist centers and underserved populations. The European Union can benefit from harmonized rare-disease standards, registries, and cross-border expert consultation. G7 health systems generally possess advanced diagnostic and intensive-care infrastructure, yet fragmentation and unequal access can still affect patients. GCC countries are positioned to expand genetic services, specialist networks, and family counseling, while regional collaboration may improve continuity. NATO members collectively represent varied health systems, making interoperable emergency guidance and shared expertise valuable for mobile or cross-border populations.

Country-Level Progress Depends on Screening Policy, Referral Networks, and Treatment Access

Australia has established rare-disease and metabolic expertise, with considerable geographic distance influencing referral and emergency coordination. Brazil and Mexico continue to need broader access to specialist diagnosis, genetic testing, and metabolic emergency care beyond major centers. Canada and the United States have experienced metabolic programs, but regional distribution, coverage, and transition between pediatric and adult services remain relevant. China and India are expanding rare-disease capabilities while facing large population, laboratory-access, and regional-equity challenges. France, Germany, Italy, Spain, and the United Kingdom have specialized centers and structured rare-disease pathways, although national approaches to screening, reimbursement, and data sharing differ. Japan and South Korea have advanced clinical and laboratory systems, with continued emphasis on early recognition and coordinated long-term follow-up. Russia’s access to specialized testing and treatment may vary by region, making referral infrastructure and consistent supply planning important.

Industry Leaders Should Prioritize Rapid Recognition, Reliable Supply, and Patient-Centered Evidence

Leaders should strengthen clinician education on unexplained hyperammonemia, publish concise emergency protocols, and support referral pathways linking community facilities with metabolic centers. Diagnostic strategies should combine biochemical testing with appropriately interpreted molecular analysis and genetic counseling. Care programs should address nutrition, adherence, illness prevention, reproductive counseling, psychosocial support, and transition to adult services. Evidence generation should use interoperable registries, meaningful patient-reported outcomes, and transparent assessment of real-world treatment effectiveness. Organizations should also plan for supply continuity, responsible digital and AI governance, and collaboration with patient communities and public-health authorities to reduce geographic and socioeconomic disparities.

Methodology: Evidence-Based Synthesis of Clinical, Health-System, and Policy Considerations

This executive summary uses the condition definition supplied in the market reference and synthesizes established clinical and public-health knowledge concerning NAGS deficiency, urea-cycle disorders, hyperammonemia, genetic diagnosis, specialist care, and rare-disease systems. The analysis is structured across the requested regions, international groups, and countries, emphasizing documented disease-management challenges and system-level priorities. It intentionally excludes market estimates, market sizing, market shares, forecasts, and company-specific claims. Statements are framed conservatively where practices differ by jurisdiction, and rare-disease variability is acknowledged rather than generalized beyond the available evidence.

Coordinated Rare-Disease Care Is the Central Opportunity in NAGS Deficiency

NAGS deficiency requires rapid recognition, precise diagnosis, sustained metabolic management, and coordinated support across the patient journey. The most consequential improvements are likely to come from reducing diagnostic delay, strengthening specialist and laboratory networks, ensuring dependable access to appropriate treatment and nutrition services, and using data responsibly to improve care. Regional and country differences mean that implementation should be adapted to local capacity, but the core objective is consistent: prevent hyperammonemic injury and enable patients and families to receive timely, informed, and continuous care.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. N-Acetylglutamate Synthetase Deficiency Market, by Treatment Type
7.1. Introduction
7.2. Enzyme Replacement Therapy
7.2.1. Intravenous Administration
7.2.2. Subcutaneous Administration
7.3. Gene Therapy
7.3.1. AAV-Based Therapy
7.3.2. Lentiviral-Based Therapy
7.4. Supportive Care
7.4.1. Nutritional Support
7.4.2. Symptom Management
8. N-Acetylglutamate Synthetase Deficiency Market, by Age Group
8.1. Introduction
8.2. Adults
8.2.1. Middle-Aged Adults
8.2.2. Young Adults
8.3. Geriatrics
8.4. Pediatrics
8.4.1. Children
8.4.2. Neonates
9. N-Acetylglutamate Synthetase Deficiency Market, by End User
9.1. Introduction
9.2. Home Care
9.2.1. Home Infusion Services
9.2.2. Remote Monitoring Services
9.3. Hospitals
9.3.1. Secondary Care Centers
9.3.2. Tertiary Care Centers
9.4. Specialty Clinics
9.4.1. Genetic Disorder Clinics
9.4.2. Metabolic Disorder Clinics
10. N-Acetylglutamate Synthetase Deficiency Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.2.1. Inpatient Pharmacy
10.2.2. Outpatient Pharmacy
10.3. Online Pharmacy
10.3.1. Direct-to-Patient Portals
10.3.2. Third-Party Marketplaces
10.4. Retail Pharmacy
10.4.1. Chain Pharmacy
10.4.2. Independent Pharmacy
11. N-Acetylglutamate Synthetase Deficiency Market, by Region
11.1. Introduction
11.2. Asia-Pacific
11.3. North America
11.4. Latin America
11.5. Europe
11.6. Middle East
11.7. Africa
12. N-Acetylglutamate Synthetase Deficiency Market, by Group
12.1. Introduction
12.2. ASEAN
12.3. GCC
12.4. European Union
12.5. BRICS
12.6. G7
12.7. NATO
13. N-Acetylglutamate Synthetase Deficiency Market, by Country
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. United Kingdom
13.7. Germany
13.8. France
13.9. Russia
13.10. Italy
13.11. Spain
13.12. China
13.13. India
13.14. Japan
13.15. Australia
13.16. South Korea
14. Competitive Landscape
14.1. Market Share Analysis, 2025
14.2. Market Concentration Analysis, 2025
14.2.1. Concentration Ratio (CR)
14.2.2. Herfindahl Hirschman Index (HHI)
14.3. Recent Developments & Impact Analysis, 2025
14.4. Product Portfolio Analysis, 2025
14.5. Benchmarking Analysis, 2025
15. Company Profiles
15.1. AmmoniaCare Inc.
15.2. Ascendis Pharma A/S
15.3. Bayer AG
15.4. BioMarin Pharmaceutical Inc.
15.5. Hoffmann-La Roche Ltd.
15.6. Horizon Therapeutics plc
15.7. Merck & Co., Inc.
15.8. Novartis AG
15.9. Pfizer Inc.
15.10. Sanofi S.A.
15.11. Sarepta Therapeutics, Inc.
15.12. Sobi
15.13. Takeda Pharmaceutical Company Limited
15.14. Ultragenyx Pharmaceutical Inc.
15.15. Vertex Pharmaceuticals Incorporated
16. Key Experts
LIST OF FIGURES
FIGURE 1. Global N-Acetylglutamate Synthetase Deficiency Market, Years Considered for the Study
FIGURE 2. Global N-Acetylglutamate Synthetase Deficiency Market, Research Design
FIGURE 3. Global N-Acetylglutamate Synthetase Deficiency Market, Research Framework
FIGURE 4. Global N-Acetylglutamate Synthetase Deficiency Market, Data Triangulation
FIGURE 5. Global N-Acetylglutamate Synthetase Deficiency Market Size, 2017-2032 (USD Million)
FIGURE 6. Global N-Acetylglutamate Synthetase Deficiency Market Size, by Treatment Type, 2025 vs 2032 (%)
FIGURE 7. Global N-Acetylglutamate Synthetase Deficiency Market Size, by Treatment Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global N-Acetylglutamate Synthetase Deficiency Market Size, by Age Group, 2025 vs 2032 (%)
FIGURE 9. Global N-Acetylglutamate Synthetase Deficiency Market Size, by Age Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global N-Acetylglutamate Synthetase Deficiency Market Size, by End User, 2025 vs 2032 (%)
FIGURE 11. Global N-Acetylglutamate Synthetase Deficiency Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global N-Acetylglutamate Synthetase Deficiency Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 13. Global N-Acetylglutamate Synthetase Deficiency Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global N-Acetylglutamate Synthetase Deficiency Market Size, by Region, 2025 vs 2032 (%)
FIGURE 15. Global N-Acetylglutamate Synthetase Deficiency Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global N-Acetylglutamate Synthetase Deficiency Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 17. Global N-Acetylglutamate Synthetase Deficiency Market Size, by Country, 2025 vs 2032 (%)
FIGURE 18. Global N-Acetylglutamate Synthetase Deficiency Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global N-Acetylglutamate Synthetase Deficiency Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global N-Acetylglutamate Synthetase Deficiency Market Segmentation & Coverage
TABLE 2. Global N-Acetylglutamate Synthetase Deficiency Market Size, 2017-2032 (USD Million)
TABLE 3. Global N-Acetylglutamate Synthetase Deficiency Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 4. Global Enzyme Replacement Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Enzyme Replacement Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Enzyme Replacement Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Intravenous Administration Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Intravenous Administration Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Intravenous Administration Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Subcutaneous Administration Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Subcutaneous Administration Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Subcutaneous Administration Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Gene Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Gene Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Gene Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global AAV-Based Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global AAV-Based Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global AAV-Based Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Lentiviral-Based Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Lentiviral-Based Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Lentiviral-Based Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Supportive Care Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Supportive Care Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Supportive Care Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Nutritional Support Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Nutritional Support Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Nutritional Support Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Symptom Management Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Symptom Management Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Symptom Management Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global N-Acetylglutamate Synthetase Deficiency Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 32. Global Adults Market Size, by Region, 2017-2032 (USD Million)
TABLE 33. Global Adults Market Size, by Group, 2017-2032 (USD Million)
TABLE 34. Global Adults Market Size, by Country, 2017-2032 (USD Million)
TABLE 35. Global Middle-Aged Adults Market Size, by Region, 2017-2032 (USD Million)
TABLE 36. Global Middle-Aged Adults Market Size, by Group, 2017-2032 (USD Million)
TABLE 37. Global Middle-Aged Adults Market Size, by Country, 2017-2032 (USD Million)
TABLE 38. Global Young Adults Market Size, by Region, 2017-2032 (USD Million)
TABLE 39. Global Young Adults Market Size, by Group, 2017-2032 (USD Million)
TABLE 40. Global Young Adults Market Size, by Country, 2017-2032 (USD Million)
TABLE 41. Global Geriatrics Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Geriatrics Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Geriatrics Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global Pediatrics Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global Pediatrics Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global Pediatrics Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global Children Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global Children Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global Children Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global Neonates Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Global Neonates Market Size, by Group, 2017-2032 (USD Million)
TABLE 52. Global Neonates Market Size, by Country, 2017-2032 (USD Million)
TABLE 53. Global N-Acetylglutamate Synthetase Deficiency Market Size, by End User, 2017-2032 (USD Million)
TABLE 54. Global Home Care Market Size, by Region, 2017-2032 (USD Million)
TABLE 55. Global Home Care Market Size, by Group, 2017-2032 (USD Million)
TABLE 56. Global Home Care Market Size, by Country, 2017-2032 (USD Million)
TABLE 57. Global Home Infusion Services Market Size, by Region, 2017-2032 (USD Million)
TABLE 58. Global Home Infusion Services Market Size, by Group, 2017-2032 (USD Million)
TABLE 59. Global Home Infusion Services Market Size, by Country, 2017-2032 (USD Million)
TABLE 60. Global Remote Monitoring Services Market Size, by Region, 2017-2032 (USD Million)
TABLE 61. Global Remote Monitoring Services Market Size, by Group, 2017-2032 (USD Million)
TABLE 62. Global Remote Monitoring Services Market Size, by Country, 2017-2032 (USD Million)
TABLE 63. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 64. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 65. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 66. Global Secondary Care Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 67. Global Secondary Care Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 68. Global Secondary Care Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 69. Global Tertiary Care Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 70. Global Tertiary Care Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 71. Global Tertiary Care Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 72. Global Specialty Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 73. Global Specialty Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 74. Global Specialty Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 75. Global Genetic Disorder Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 76. Global Genetic Disorder Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 77. Global Genetic Disorder Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 78. Global Metabolic Disorder Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 79. Global Metabolic Disorder Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 80. Global Metabolic Disorder Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 81. Global N-Acetylglutamate Synthetase Deficiency Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 82. Global Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 83. Global Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 84. Global Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 85. Global Inpatient Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 86. Global Inpatient Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 87. Global Inpatient Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 88. Global Outpatient Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 89. Global Outpatient Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 90. Global Outpatient Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 91. Global Online Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 92. Global Online Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 93. Global Online Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 94. Global Direct-to-Patient Portals Market Size, by Region, 2017-2032 (USD Million)
TABLE 95. Global Direct-to-Patient Portals Market Size, by Group, 2017-2032 (USD Million)
TABLE 96. Global Direct-to-Patient Portals Market Size, by Country, 2017-2032 (USD Million)
TABLE 97. Global Third-Party Marketplaces Market Size, by Region, 2017-2032 (USD Million)
TABLE 98. Global Third-Party Marketplaces Market Size, by Group, 2017-2032 (USD Million)
TABLE 99. Global Third-Party Marketplaces Market Size, by Country, 2017-2032 (USD Million)
TABLE 100. Global Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 101. Global Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 102. Global Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 103. Global Chain Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 104. Global Chain Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 105. Global Chain Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 106. Global Independent Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 107. Global Independent Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 108. Global Independent Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 109. Global N-Acetylglutamate Synthetase Deficiency Market Size, by Region, 2017-2032 (USD Million)
TABLE 110. Asia-Pacific N-Acetylglutamate Synthetase Deficiency Market Size, by Region, 2017-2032 (USD Million)
TABLE 111. Asia-Pacific N-Acetylglutamate Synthetase Deficiency Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 112. Asia-Pacific N-Acetylglutamate Synthetase Deficiency Market Size, by Enzyme Replacement Therapy, 2017-2032 (USD Million)
TABLE 113. Asia-Pacific N-Acetylglutamate Synthetase Deficiency Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 114. Asia-Pacific N-Acetylglutamate Synthetase Deficiency Market Size, by Supportive Care, 2017-2032 (USD Million)
TABLE 115. Asia-Pacific N-Acetylglutamate Synthetase Deficiency Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 116. Asia-Pacific N-Acetylglutamate Synthetase Deficiency Market Size, by Adults, 2017-2032 (USD Million)
TABLE 117. Asia-Pacific N-Acetylglutamate Synthetase Deficiency Market Size, by Pediatrics, 2017-2032 (USD Million)
TABLE 118. Asia-Pacific N-Acetylglutamate Synthetase Deficiency Market Size, by End User, 2017-2032 (USD Million)
TABLE 119. Asia-Pacific N-Acetylglutamate Synthetase Deficiency Market Size, by Home Care, 2017-2032 (USD Million)
TABLE 120. Asia-Pacific N-Acetylglutamate Synthetase Deficiency Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 121. Asia-Pacific N-Acetylglutamate Synthetase Deficiency Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 122. Asia-Pacific N-Acetylglutamate Synthetase Deficiency Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 123. Asia-Pacific N-Acetylglutamate Synthetase Deficiency Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 124. Asia-Pacific N-Acetylglutamate Synthetase Deficiency Market Size, by Online Pharmacy, 2017-2032 (USD Million)
TABLE 125. Asia-Pacific N-Acetylglutamate Synthetase Deficiency Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 126. North America N-Acetylglutamate Synthetase Deficiency Market Size, by Region, 2017-2032 (USD Million)
TABLE 127. North America N-Acetylglutamate Synthetase Deficiency Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 128. North America N-Acetylglutamate Synthetase Deficiency Market Size, by Enzyme Replacement Therapy, 2017-2032 (USD Million)
TABLE 129. North America N-Acetylglutamate Synthetase Deficiency Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 130. North America N-Acetylglutamate Synthetase Deficiency Market Size, by Supportive Care, 2017-2032 (USD Million)
TABLE 131. North America N-Acetylglutamate Synthetase Deficiency Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 132. North America N-Acetylglutamate Synthetase Deficiency Market Size, by Adults, 2017-2032 (USD Million)
TABLE 133. North America N-Acetylglutamate Synthetase Deficiency Market Size, by Pediatrics, 2017-2032 (USD Million)
TABLE 134. North America N-Acetylglutamate Synthetase Deficiency Market Size, by End User, 2017-2032 (USD Million)
TABLE 135. North America N-Acetylglutamate Synthetase Deficiency Market Size, by Home Care, 2017-2032 (USD Million)
TABLE 136. North America N-Acetylglutamate Synthetase Deficiency Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 137. North America N-Acetylglutamate Synthetase Deficiency Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 138. North America N-Acetylglutamate Synthetase Deficiency Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 139. North America N-Acetylglutamate Synthetase Deficiency Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 140. North America N-Acetylglutamate Synthetase Deficiency Market Size, by Online Pharmacy, 2017-2032 (USD Million)
TABLE 141. North America N-Acetylglutamate Synthetase Deficiency Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 142. Latin America N-Acetylglutamate Synthetase Deficiency Market Size, by Region, 2017-2032 (USD Million)
TABLE 143. Latin America N-Acetylglutamate Synthetase Deficiency Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 144. Latin America N-Acetylglutamate Synthetase Deficiency Market Size, by Enzyme Replacement Therapy, 2017-2032 (USD Million)
TABLE 145. Latin America N-Acetylglutamate Synthetase Deficiency Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 146. Latin America N-Acetylglutamate Synthetase Deficiency Market Size, by Supportive Care, 2017-2032 (USD Million)
TABLE 147. Latin America N-Acetylglutamate Synthetase Deficiency Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 148. Latin America N-Acetylglutamate Synthetase Deficiency Market Size, by Adults, 2017-2032 (USD Million)
TABLE 149. Latin America N-Acetylglutamate Synthetase Deficiency Market Size, by Pediatrics, 2017-2032 (USD Million)
TABLE 150. Latin America N-Acetylglutamate Synthetase Deficiency Market Size, by End User, 2017-2032 (USD Million)
TABLE 151. Latin America N-Acetylglutamate Synthetase Deficiency Market Size, by Home Care, 2017-2032 (USD Million)
TABLE 152. Latin America N-Acetylglutamate Synthetase Deficiency Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 153. Latin America N-Acetylglutamate Synthetase Deficiency Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 154. Latin America N-Acetylglutamate Synthetase Deficiency Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 155. Latin America N-Acetylglutamate Synthetase Deficiency Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 156. Latin America N-Acetylglutamate Synthetase Deficiency Market Size, by Online Pharmacy, 2017-2032 (USD Million)
TABLE 157. Latin America N-Acetylglutamate Synthetase Deficiency Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 158. Europe N-Acetylglutamate Synthetase Deficiency Market Size, by Region, 2017-2032 (USD Million)
TABLE 159. Europe N-Acetylglutamate Synthetase Deficiency Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 160. Europe N-Acetylglutamate Synthetase Deficiency Market Size, by Enzyme Replacement Therapy, 2017-2032 (USD Million)
TABLE 161. Europe N-Acetylglutamate Synthetase Deficiency Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 162. Europe N-Acetylglutamate Synthetase Deficiency Market Size, by Supportive Care, 2017-2032 (USD Million)
TABLE 163. Europe N-Acetylglutamate Synthetase Deficiency Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 164. Europe N-Acetylglutamate Synthetase Deficiency Market Size, by Adults, 2017-2032 (USD Million)
TABLE 165. Europe N-Acetylglutamate Synthetase Deficiency Market Size, by Pediatrics, 2017-2032 (USD Million)
TABLE 166. Europe N-Acetylglutamate Synthetase Deficiency Market Size, by End User, 2017-2032 (USD Million)
TABLE 167. Europe N-Acetylglutamate Synthetase Deficiency Market Size, by Home Care, 2017-2032 (USD Million)
TABLE 168. Europe N-Acetylglutamate Synthetase Deficiency Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 169. Europe N-Acetylglutamate Synthetase Deficiency Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 170. Europe N-Acetylglutamate Synthetase Deficiency Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 171. Europe N-Acetylglutamate Synthetase Deficiency Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 172. Europe N-Acetylglutamate Synthetase Deficiency Market Size, by Online Pharmacy, 2017-2032 (USD Million)
TABLE 173. Europe N-Acetylglutamate Synthetase Deficiency Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 174. Middle East N-Acetylglutamate Synthetase Deficiency Market Size, by Region, 2017-2032 (USD Million)
TABLE 175. Middle East N-Acetylglutamate Synthetase Deficiency Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 176. Middle East N-Acetylglutamate Synthetase Deficiency Market Size, by Enzyme Replacement Therapy, 2017-2032 (USD Million)
TABLE 177. Middle East N-Acetylglutamate Synthetase Deficiency Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 178. Middle East N-Acetylglutamate Synthetase Deficiency Market Size, by Supportive Care, 2017-2032 (USD Million)
TABLE 179. Middle East N-Acetylglutamate Synthetase Deficiency Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 180. Middle East N-Acetylglutamate Synthetase Deficiency Market Size, by Adults, 2017-2032 (USD Million)
TABLE 181. Middle East N-Acetylglutamate Synthetase Deficiency Market Size, by Pediatrics, 2017-2032 (USD Million)
TABLE 182. Middle East N-Acetylglutamate Synthetase Deficiency Market Size, by End User, 2017-2032 (USD Million)
TABLE 183. Middle East N-Acetylglutamate Synthetase Deficiency Market Size, by Home Care, 2017-2032 (USD Million)
TABLE 184. Middle East N-Acetylglutamate Synthetase Deficiency Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 185. Middle East N-Acetylglutamate Synthetase Deficiency Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 186. Middle East N-Acetylglutamate Synthetase Deficiency Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 187. Middle East N-Acetylglutamate Synthetase Deficiency Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 188. Middle East N-Acetylglutamate Synthetase Deficiency Market Size, by Online Pharmacy, 2017-2032 (USD Million)
TABLE 189. Middle East N-Acetylglutamate Synthetase Deficiency Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 190. Africa N-Acetylglutamate Synthetase Deficiency Market Size, by Region, 2017-2032 (USD Million)
TABLE 191. Africa N-Acetylglutamate Synthetase Deficiency Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 192. Africa N-Acetylglutamate Synthetase Deficiency Market Size, by Enzyme Replacement Therapy, 2017-2032 (USD Million)
TABLE 193. Africa N-Acetylglutamate Synthetase Deficiency Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 194. Africa N-Acetylglutamate Synthetase Deficiency Market Size, by Supportive Care, 2017-2032 (USD Million)
TABLE 195. Africa N-Acetylglutamate Synthetase Deficiency Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 196. Africa N-Acetylglutamate Synthetase Deficiency Market Size, by Adults, 2017-2032 (USD Million)
TABLE 197. Africa N-Acetylglutamate Synthetase Deficiency Market Size, by Pediatrics, 2017-2032 (USD Million)
TABLE 198. Africa N-Acetylglutamate Synthetase Deficiency Market Size, by End User, 2017-2032 (USD Million)
TABLE 199. Africa N-Acetylglutamate Synthetase Deficiency Market Size, by Home Care, 2017-2032 (USD Million)
TABLE 200. Africa N-Acetylglutamate Synthetase Deficiency Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 201. Africa N-Acetylglutamate Synthetase Deficiency Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 202. Africa N-Acetylglutamate Synthetase Deficiency Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 203. Africa N-Acetylglutamate Synthetase Deficiency Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 204. Africa N-Acetylglutamate Synthetase Deficiency Market Size, by Online Pharmacy, 2017-2032 (USD Million)
TABLE 205. Africa N-Acetylglutamate Synthetase Deficiency Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 206. Global N-Acetylglutamate Synthetase Deficiency Market Size, by Group, 2017-2032 (USD Million)
TABLE 207. ASEAN N-Acetylglutamate Synthetase Deficiency Market Size, by Group, 2017-2032 (USD Million)
TABLE 208. ASEAN N-Acetylglutamate Synthetase Deficiency Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 209. ASEAN N-Acetylglutamate Synthetase Deficiency Market Size, by Enzyme Replacement Therapy, 2017-2032 (USD Million)
TABLE 210. ASEAN N-Acetylglutamate Synthetase Deficiency Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 211. ASEAN N-Acetylglutamate Synthetase Deficiency Market Size, by Supportive Care, 2017-2032 (USD Million)
TABLE 212. ASEAN N-Acetylglutamate Synthetase Deficiency Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 213. ASEAN N-Acetylglutamate Synthetase Deficiency Market Size, by Adults, 2017-2032 (USD Million)
TABLE 214. ASEAN N-Acetylglutamate Synthetase Deficiency Market Size, by Pediatrics, 2017-2032 (USD Million)
TABLE 215. ASEAN N-Acetylglutamate Synthetase Deficiency Market Size, by End User, 2017-2032 (USD Million)
TABLE 216. ASEAN N-Acetylglutamate Synthetase Deficiency Market Size, by Home Care, 2017-2032 (USD Million)
TABLE 217. ASEAN N-Acetylglutamate Synthetase Deficiency Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 218. ASEAN N-Acetylglutamate Synthetase Deficiency Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 219. ASEAN N-Acetylglutamate Synthetase Deficiency Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 220. ASEAN N-Acetylglutamate Synthetase Deficiency Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 221. ASEAN N-Acetylglutamate Synthetase Deficiency Market Size, by Online Pharmacy, 2017-2032 (USD Million)
TABLE 222. ASEAN N-Acetylglutamate Synthetase Deficiency Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 223. GCC N-Acetylglutamate Synthetase Deficiency Market Size, by Group, 2017-2032 (USD Million)
TABLE 224. GCC N-Acetylglutamate Synthetase Deficiency Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 225. GCC N-Acetylglutamate Synthetase Deficiency Market Size, by Enzyme Replacement Therapy, 2017-2032 (USD Million)
TABLE 226. GCC N-Acetylglutamate Synthetase Deficiency Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 227. GCC N-Acetylglutamate Synthetase Deficiency Market Size, by Supportive Care, 2017-2032 (USD Million)
TABLE 228. GCC N-Acetylglutamate Synthetase Deficiency Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 229. GCC N-Acetylglutamate Synthetase Deficiency Market Size, by Adults, 2017-2032 (USD Million)
TABLE 230. GCC N-Acetylglutamate Synthetase Deficiency Market Size, by Pediatrics, 2017-2032 (USD Million)
TABLE 231. GCC N-Acetylglutamate Synthetase Deficiency Market Size, by End User, 2017-2032 (USD Million)
TABLE 232. GCC N-Acetylglutamate Synthetase Deficiency Market Size, by Home Care, 2017-2032 (USD Million)
TABLE 233. GCC N-Acetylglutamate Synthetase Deficiency Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 234. GCC N-Acetylglutamate Synthetase Deficiency Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 235. GCC N-Acetylglutamate Synthetase Deficiency Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 236. GCC N-Acetylglutamate Synthetase Deficiency Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 237. GCC N-Acetylglutamate Synthetase Deficiency Market Size, by Online Pharmacy, 2017-2032 (USD Million)
TABLE 238. GCC N-Acetylglutamate Synthetase Deficiency Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 239. European Union N-Acetylglutamate Synthetase Deficiency Market Size, by Group, 2017-2032 (USD Million)
TABLE 240. European Union N-Acetylglutamate Synthetase Deficiency Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 241. European Union N-Acetylglutamate Synthetase Deficiency Market Size, by Enzyme Replacement Therapy, 2017-2032 (USD Million)
TABLE 242. European Union N-Acetylglutamate Synthetase Deficiency Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 243. European Union N-Acetylglutamate Synthetase Deficiency Market Size, by Supportive Care, 2017-2032 (USD Million)
TABLE 244. European Union N-Acetylglutamate Synthetase Deficiency Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 245. European Union N-Acetylglutamate Synthetase Deficiency Market Size, by Adults, 2017-2032 (USD Million)
TABLE 246. European Union N-Acetylglutamate Synthetase Deficiency Market Size, by Pediatrics, 2017-2032 (USD Million)
TABLE 247. European Union N-Acetylglutamate Synthetase Deficiency Market Size, by End User, 2017-2032 (USD Million)
TABLE 248. European Union N-Acetylglutamate Synthetase Deficiency Market Size, by Home Care, 2017-2032 (USD Million)
TABLE 249. European Union N-Acetylglutamate Synthetase Deficiency Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 250. European Union N-Acetylglutamate Synthetase Deficiency Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 251. European Union N-Acetylglutamate Synthetase Deficiency Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 252. European Union N-Acetylglutamate Synthetase Deficiency Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 253. European Union N-Acetylglutamate Synthetase Deficiency Market Size, by Online Pharmacy, 2017-2032 (USD Million)
TABLE 254. European Union N-Acetylglutamate Synthetase Deficiency Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 255. BRICS N-Acetylglutamate Synthetase Deficiency Market Size, by Group, 2017-2032 (USD Million)
TABLE 256. BRICS N-Acetylglutamate Synthetase Deficiency Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 257. BRICS N-Acetylglutamate Synthetase Deficiency Market Size, by Enzyme Replacement Therapy, 2017-2032 (USD Million)
TABLE 258. BRICS N-Acetylglutamate Synthetase Deficiency Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 259. BRICS N-Acetylglutamate Synthetase Deficiency Market Size, by Supportive Care, 2017-2032 (USD Million)
TABLE 260. BRICS N-Acetylglutamate Synthetase Deficiency Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 261. BRICS N-Acetylglutamate Synthetase Deficiency Market Size, by Adults, 2017-2032 (USD Million)
TABLE 262. BRICS N-Acetylglutamate Synthetase Deficiency Market Size, by Pediatrics, 2017-2032 (USD Million)
TABLE 263. BRICS N-Acetylglutamate Synthetase Deficiency Market Size, by End User, 2017-2032 (USD Million)
TABLE 264. BRICS N-Acetylglutamate Synthetase Deficiency Market Size, by Home Care, 2017-2032 (USD Million)
TABLE 265. BRICS N-Acetylglutamate Synthetase Deficiency Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 266. BRICS N-Acetylglutamate Synthetase Deficiency Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 267. BRICS N-Acetylglutamate Synthetase Deficiency Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 268. BRICS N-Acetylglutamate Synthetase Deficiency Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 269. BRICS N-Acetylglutamate Synthetase Deficiency Market Size, by Online Pharmacy, 2017-2032 (USD Million)
TABLE 270. BRICS N-Acetylglutamate Synthetase Deficiency Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 271. G7 N-Acetylglutamate Synthetase Deficiency Market Size, by Group, 2017-2032 (USD Million)
TABLE 272. G7 N-Acetylglutamate Synthetase Deficiency Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 273. G7 N-Acetylglutamate Synthetase Deficiency Market Size, by Enzyme Replacement Therapy, 2017-2032 (USD Million)
TABLE 274. G7 N-Acetylglutamate Synthetase Deficiency Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 275. G7 N-Acetylglutamate Synthetase Deficiency Market Size, by Supportive Care, 2017-2032 (USD Million)
TABLE 276. G7 N-Acetylglutamate Synthetase Deficiency Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 277. G7 N-Acetylglutamate Synthetase Deficiency Market Size, by Adults, 2017-2032 (USD Million)
TABLE 278. G7 N-Acetylglutamate Synthetase Deficiency Market Size, by Pediatrics, 2017-2032 (USD Million)
TABLE 279. G7 N-Acetylglutamate Synthetase Deficiency Market Size, by End User, 2017-2032 (USD Million)
TABLE 280. G7 N-Acetylglutamate Synthetase Deficiency Market Size, by Home Care, 2017-2032 (USD Million)
TABLE 281. G7 N-Acetylglutamate Synthetase Deficiency Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 282. G7 N-Acetylglutamate Synthetase Deficiency Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 283. G7 N-Acetylglutamate Synthetase Deficiency Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 284. G7 N-Acetylglutamate Synthetase Deficiency Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 285. G7 N-Acetylglutamate Synthetase Deficiency Market Size, by Online Pharmacy, 2017-2032 (USD Million)
TABLE 286. G7 N-Acetylglutamate Synthetase Deficiency Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 287. NATO N-Acetylglutamate Synthetase Deficiency Market Size, by Group, 2017-2032 (USD Million)
TABLE 288. NATO N-Acetylglutamate Synthetase Deficiency Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 289. NATO N-Acetylglutamate Synthetase Deficiency Market Size, by Enzyme Replacement Therapy, 2017-2032 (USD Million)
TABLE 290. NATO N-Acetylglutamate Synthetase Deficiency Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 291. NATO N-Acetylglutamate Synthetase Deficiency Market Size, by Supportive Care, 2017-2032 (USD Million)
TABLE 292. NATO N-Acetylglutamate Synthetase Deficiency Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 293. NATO N-Acetylglutamate Synthetase Deficiency Market Size, by Adults, 2017-2032 (USD Million)
TABLE 294. NATO N-Acetylglutamate Synthetase Deficiency Market Size, by Pediatrics, 2017-2032 (USD Million)
TABLE 295. NATO N-Acetylglutamate Synthetase Deficiency Market Size, by End User, 2017-2032 (USD Million)
TABLE 296. NATO N-Acetylglutamate Synthetase Deficiency Market Size, by Home Care, 2017-2032 (USD Million)
TABLE 297. NATO N-Acetylglutamate Synthetase Deficiency Market Size, by Hospitals, 2017-2032 (USD Million)
TABLE 298. NATO N-Acetylglutamate Synthetase Deficiency Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 299. NATO N-Acetylglutamate Synthetase Deficiency Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 300. NATO N-Acetylglutamate Synthetase Deficiency Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 301. NATO N-Acetylglutamate Synthetase Deficiency Market Size, by Online Pharmacy, 2017-2032 (USD Million)
TABLE 302. NATO N-Acetylglutamate Synthetase Deficiency Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 303. Global N-Acetylglutamate Synthetase Deficiency Market Size, by Country, 2017-2032 (USD Million)
TABLE 304. United States N-Acetylglutamate Synthetase Deficiency Market Size, 2017-2032 (USD Million)
TABLE 305. United States N-Acetylglutamate Synthetase Deficiency Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 306. United States N-Acetylglutamate Synthetase Deficiency Market Size, by Enzyme Replacement Therapy, 2017-2032 (USD Million)
TABLE 307. United States N-Acetylglutamate Synthetase Deficiency Market Size, by Gene Therapy, 2017-2032 (USD Million)
TABLE 308. United States N-Acetylglutamate Synthetase Deficiency Market Size, by Supportive Care, 2017-2032 (USD Million)
TABLE 309. United States N-Acetylglutamate Synthetase Deficiency Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 310. United States N-Acetylglutamate Synthetase Deficiency Market Size, by Adults, 2017-2032 (USD Million)
TABLE 311. United States N-Acetylglutamate Synthetase Deficiency Market Size, by Pediatrics, 2017-2032 (USD Million)
TABLE 312. United States N-Acetylglutamate Synthetase Deficiency Market Size, by End User, 2017-2032 (USD Million)
TABLE 313. United States N-Acetylglutamate Synthetase Deficiency Market Size, by Home Care, 2017-2032 (USD Million)
TABLE 314. United States N-Acetylglutamate Synthetase Deficiency Market S

Companies Mentioned

  • AmmoniaCare Inc.
  • Ascendis Pharma A/S
  • Bayer AG
  • BioMarin Pharmaceutical Inc.
  • Hoffmann-La Roche Ltd.
  • Horizon Therapeutics plc
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Sarepta Therapeutics, Inc.
  • Sobi
  • Takeda Pharmaceutical Company Limited
  • Ultragenyx Pharmaceutical Inc.
  • Vertex Pharmaceuticals Incorporated

Related Topics

Related Reports

Carglumic Acid Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035 - Product Image

Carglumic Acid Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035

  • Report
  • 135 Pages
  • Global
From
Carglumic Acid - Global Strategic Business Report - Product Image

Carglumic Acid - Global Strategic Business Report

  • Report
  • 461 Pages
  • Global
From
Carglumic Acid Market - Global Forecast 2026-2032 - Product Image

Carglumic Acid Market - Global Forecast 2026-2032

  • Report
  • 180 Pages
  • Global
From
Carglumic Acid Dispersible Tablets Market - Global Forecast 2026-2032 - Product Image

Carglumic Acid Dispersible Tablets Market - Global Forecast 2026-2032

  • Report
  • 180 Pages
  • Global
From
Nutropin AQ Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts - Product Image

Nutropin AQ Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

  • Report
  • 250 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.